Shionogi

December 02, 2019

Go or no go? Vascepa’s finale and Allergan's pain relief

Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.

Go or no go? Vascepa’s finale and Allergan's pain relief

Go or no go? Agile and Lipocine hope to make it third time lucky

Roche tries again with a new pill for flu

Upcoming events – Dova’s US verdict and Glaxo’s valuable HIV doublet data

Seattle disappoints Puma bulls with Cascadian takeout

Therapy focus – No safe haven for bio in spinocerebellar ataxia

Axovant scraps Alzheimer’s bid – now back to the amyloid hypothesis

Flurry of FDA activity raises hopes for 2017 approval tally

Upcoming events – Achaogen’s antibiotic and Nektar tries out its opioid again

Rigel gets another chance with fostamatinib

Viiv-Bristol HIV deal ramps up asset swap stakes

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Shock revelation sees Biogen erase its aducanumab losses

Vertex’s double cystic fibrosis surprise

Bristol might play a role in front-line lung cancer after all

Bloated on arrival? Biotech's weightiest new issues

Uncovering biopharma’s hidden treasures